ARTLNCMHealthcare·Biotechnology#556 in industry

Artelo Biosciences, Inc.

-31.0% · 90d

$3.77

-0.26 (-6.57%)

After-Hours $3.73(-0.04)

News

(2)

April 2026

Apr 7, 20262 weeks ago8-KHealthcare

ARTELO BIOSCIENCES, INC. — 8-K Filing

ARTLARTELO BIOSCIENCES, INC.

# 🧾 What This Document Is This is a Form 8-K filing, which companies use to announce major news to investors. This specific filing contains a press release where **Artelo Biosciences announces it has officially fixed its compliance problems with the Nasdaq stock exchange**. Think of it as the compa

Read summaryView on SEC EDGAR

March 2026

Mar 30, 20260 months ago8-KHealthcare

ARTELO BIOSCIENCES, INC. — 8-K Filing

ARTLARTELO BIOSCIENCES, INC.

# 🧾 What This Document Is This is an **8-K filing**, which is a report companies file with the SEC to announce major events that shareholders should know about. Attached is the full **Securities Purchase Agreement (EX-10.1)**, the contract detailing a private fundraising deal. **In simple terms:**

Read summaryView on SEC EDGAR

Key Data

Market Cap$3.5M

Open$4.01

Prev Close$4.04

Day Range$3.68 – $4.12

52W Range$2.96 – $85.80

Volume293,978

P/E (TTM)—

EPS$-37.56

Dividend Yield—

Beta0.41

About

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Healthcare · Biotechnology

7 employees

artelobio.com